Inhibin A concentrations in the sera of young women during and after chemotherapy for lymphoma: Correlation with ovarian toxicity

American Journal of Reproductive Immunology

Volumn 39, Issue 1, 1998, Pages 33-40

  Blumenfeld, Zeev ^a,b   Ritter, M ^a   Shen Orr, Z ^a   Shariki, K ^a   Ben Shahar, M ^a   Haim, N ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Chemotherapy; GnRH a; Gonadotoxicity; Hypergonadotropic amenorrhea; Inhibin A; Premature ovarian failure

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACTINOMYCIN; ESTRADIOL; FOLLITROPIN; INHIBIN A; LUTEINIZING HORMONE; PREDNISONE; PROCARBAZINE; PROGESTERONE; PROLACTIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE; TRIPTORELIN; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONCEPTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOSA CELL; HODGKIN DISEASE; HORMONE BLOOD LEVEL; HUMAN; IMMUNOREACTIVITY; INTRAMUSCULAR DRUG ADMINISTRATION; MENOPAUSE; MENSTRUAL CYCLE; MENSTRUATION; NONHODGKIN LYMPHOMA; OVARY DISEASE; OVARY FUNCTION; OVULATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

EID: 0031986094     PISSN: 87558920     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0897.1998.tb00331.x     Document Type: Article

References (58)

1. Blumenfeld Z, Haim N: Prevention of gonadal damage during cytotoxic therapy. Ann Med 1997; 29:199-206.
2. Gosden RG, Rutherford AJ, Norfolk DR: Debate: Ovarian banking for cancer patients - Transmission of malignant cells in ovarian grafts. Hum Reprod 1997; 12:403.
3. Shaw J, Trounson A: Oncological implications in the replacement of ovarian tissue. Hum Reprod 1997; 12:403-405.
4. Glaser SL: Reproductive factors in Hodgkin disease in women: a review. Am J Epidemiol 1994; 139:237-246.
5. Ataya K, Moghissi K: Chemotherapy induced premature ovarian failure: medications and prevention. Steroids 1989; 54:607-626.
6. De Vita VT, Serpick AA, Carbone PP: Combination chemotherapy in the treatment of advanced Hodfkin disease. Ann Intern Med 1970; 73:881-886.
7. Devita Jr VT, Simon RM, Hubbard SM, et al.: Curability of advanced HD with chemotherapy. Ann Intern Med 198; 92:587-595.
8. Chapman RM: Effect of cytotoxic therapy on sexuality and gonadal function. Sernin Oncol 1982; 9:84-93.
9. Chapman RM, Sutcliffe SB, Malpas JS: Cytotoxic induced ovarian failure in women with Hodgkin's disease. I. Hormonal function. JAMA 1979; 242:1877-1881.
10. Kreuser ED, Xirus N, Hetzel WD, Himpel: Reproductive and endocrine gonadal capacity in patients treated with COPP chimotherapy of Hodgkin's disease. J Cancer Res Clin Oncol 1987; 113:260-266.
11. Rivkees SA, Crawford JD: The relationship of gonadal damage. JAMA 1988; 259:2123-2125.
12. Shafet SM, Beardwell CG, Morris PH, Pearson D, Orrell DH: Ovarian failure following abdominal irradiation in childhood. Br J Cancer 1976; 33:655-658.
13. Ataya KM, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ: Prevention of chemotherapy-induced varian follicular loss in rats. Cancer Res 1985; 45:3651-3656.
14. Muller U, Stahel RA: Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin lymphoma. Ann Oncol 1993; 4:399-402.
15. Johnson DH, Linde R, Hainsworth JD, et al.: Effect of a luteinizing hormone releasing hormone agonist gives during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations. Blood 1985; 65:832-836.
16. Sutcliffe SB: Cytotoxic chemotherapy and gonadal function in patients with Hodgkin disease. JAMA 1979; 242:1898,1901.
17. Waxman JH, Ahmed R, Smith D, et al.: Failure to preserve fertility in patients with Hodgkin disease. Cancer Chemother Pharmacol 1987; 19:159-162.
18. Glode LM, Robinson J, Gould SF: Protection from cyclophosphamide induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1981; 1:1132-1134.
19. Chapman RM, Sutcliffe S: The effects of chemotherapy and radiotherapy on fertility and their prevention. Recent Adv Clin Oncol 1986; 2:239-251.
20. Krepart GV, Lotocki RJ: Chemotherapy during pregnancy. In Cancer in Pregnancy, Therapeutic Guidelines, HH Allen, JA Nisker (eds). Mount Kisco, New York, Futura Publishing, 1986, pp 69-88.
21. Ataya K, Rao LV, Laurence E, Kimmel R: Luteinizing hormone-releasng hormone agonist inhibits cyclophosphamide induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995; 52:365-372.
22. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N: Preventin of irreversible chemotherapy-induced ovarian damage in young women woth lymphoma by a gonadotropin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996; 11:1620-1626.
23. Robertson D, Burger HG, Sullivan J, Cahir N, Groome N, Poncelet E, et al.: Biological and immunological characterisation of inhibin forms in human plasma. J Clin Endocrinol Metab 1996; 81:601-676.
24. Burger HG: Inhibin. Reprod Med Rev 1992; 1:1-20.
25. Porcelet E, Franchimont P: Two site enzymo-immunoassays of inhibin. Ares-Serono Symposia Series - Front Endocrinol 1994; 3:45-54.
26. Blumenfeld Z, Ritter M, Shariki K, Haim N. Inhibin-A concentrations in sera of young women during and following chemotherapy for lymphoma - correlation with overian toxicity. Presented at the 43rd annual meeting of the Society for Gynecologic Investigation, San-Diego, CA, March 20-22, 1997. J Soc Gynecol Invest (Suppl.) 4:122A.
27. Devite VT Jr, Jaffe ES, Hellman S: Hodgkin disease and the non-Hodgkin lymphomas. In Principles and Practice of Oncology, vol. 2, VT DeVita, Jr, S Hellman, SA Rosenberg (eds.)., Philadelphia, JB Lippincott, 1985, pp 1623-1709.
28. Blumenfeld Z, Barkey RJ, Youdim MBH, Brandes JM, Amit T: Growth hormone (GH)-binding protein regulation by estrogen, progesterone, and gonadotropins in human: the effect of ovulation induction with menopausal gonadotropins, GH, and gestation. J Clin Endocrinol Metab 1992; 75:1242-1249.
29. Groome NP, O'Brien M: Two-site immunoassays for inhibin and its subunits. Further applications of synthetic peptide approach. J Immunol Methods 1993; 165:167-176.
30. Groome NP, Illingworth PJ, O'Brien M, Cooke I, Ganesan TS, Baird DR, McNeilly A: Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassys. Clin Endocrinol 1994; 40:717-723.
31. Lambert-Messirian G, Hall JE, Sluss P, Taylor AL, Martin KA, Groome NP, Crowley WF, Schneyer A: Relatively low levels of dimeric inhibin circulate in men and women. J Clin Endocrinol Metab 1994; 79:45-50.
32. Muttukrishna S, Fowler PA, Groome NP, Mitchell GC, Robertson WR, Knight PG: Serum concentrations of dimeric inhibin during the spontaneous human menstrual cycle and after treatment with exogenous gonadotropin. Hum Reprod 1994; 9:1634-1642.
33. Groome NP, Illingworth PJ, O'Brien M, Priddle J, Weaver K, McNeilly AS: Quantification of Inhibin Pro-αC-containing forms in human serum by a new ultra sensitive two-site enzyme-linked immunosorbent assay. J Clin Endocrinol Matab 1995; 80:2926-2932.
34. Groome NP, Lawrence M: Preparation of monoclonal antibodies reactive with the beta-A subunit human ovarian inhibin. Hybridoma 1991; 10:309-316.
35. Groome NP, et al: Manoclonal and polyclonal antibodies reactive with the 1-32 amino terminal peptide of 32kD human ovarian inhibin. Hybridoma 1990; 9:31-42.
36. Knight PG, Muttukrishna S, Groome NP: Development and application of a two-site enzyme for the determination of "total" activin-A concentrations in serum and follicular fluid. J Endocrinol 1996; 148:267-279.
37. McLachlan RI, Robertson DM, de Kretser DM, Burger HG: Advances in the physiology of inhibin and inhibin-related peptides. Clin Endocrinol 1988; 29:77-112.
38. McLachlan RI, Robertson DM, Healy DL, Burger HG, deKretser DM: Circulating immunoreactive inhibin level during the normal menstrual cycle. J Clin Endocrinol Metab 1987; 65:954-961.
39. Woodruff TK, Krummen L, Baly D, Wong WL, Garg S, Sadik M, Davis G, Soules MR, Mather JP: Inhibin and activin-A measured in human serum. In Inhibin and Inhibin-Related Proteins - Frontiers in Endocrinology, vol. 3, HG Burger (ed). Ares-Serono Symposia, Rome, Italy, 1994, pp 55-68.
40. Hee J, McNaughton J, Bangah M, Burger HG: Premenopausal pattern of gonadotropins, immunoreactive inhibin, estradiol, and progesterone. Maturitas 1993; 18:9-20.
41. Woodruff TK, Mather JP: Inhibin, activin, and the female reproductive axis. Ann Rev Physiol 1995; 57:219-244.
42. Kreuser ED, Felsenberg D, Behles C, et al: Long term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin disease. Ann Oncol 1992; (Suppl 4):S105-S110.
43. Longo DL: The use of chemotherapy in the treatment of Hodgkin disease. Semin Oncol 1990; 17:716-435.
44. Ratcliffe MA, Lanham SA, Reld DM, Dawson AA: Bone mineral density (BMD) in patients with lymphoma: the effects of chemotherapy, intermittent corticosteroids and premature menopause. Hematol Oncol 1992; 10:181-187.
45. Ortin TT, Shoshlak CA, Donaldson SS: Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: The Stanford ecperience. Int J Radiol Oncol Biol Phys 1990; 19:873-880.
46. Backshine H, Brauner R, Thibaud E, et al.: Chemotherapy and ovarian function. Retrospective analysis in 17 girls treated for malignant tumor of hematologic disease. Arch Fr Pediatr 1986; 43:611-616.
47. Wallace WH, Shalet SM, Tellow LJ, Morrris-Jones PH: Ovarian function following the treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1993; 21:333-339.
48. Kreuser ED, Hetzel WD, Billia DO, Thiel E: Gonadal toxicity following cancer therapy in adults: Significance, diagnosis, prevention and treatment. Cancer Treat Rev 1990; 17:169-175.
49. Krause W, Pfluger KH: Treatment with the gonadotropin-releasing hormone agonist buserelin to protect spermatogenesis against cytotoxic treatment in young men. Andrologia 1989; 21:265-270.
50. Byrne J, Mulvihill JJ, Myers MH, Connelly RR, Naughton MD, Krauss MR, et al.: Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med 1987; 317:1315-1321.
51. Jarrell JF, McMahon A, Barr RD, Young Lai EV: The agonist (d-leu-6, des-gly-10) - LHRH - ethylamide does not protect the fecundity of rats exposed to high dose unilateral ovarian irradiation. Reprod Toxicol 1991; 5:385-388.
52. Nademanee A, Schmidt GM, O'Donnell MR, et al.: High dose chemoradiotherapy followed by autologous bone marrow transplantation as a consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: A pilot study. Blood 1992; 80:1130-1134.
53. Carey PJ, Proctor SJ, Hamilton PJ: Autologous bone marrow transplantation for high grade lymphoid malignancy using melphalan/irradiation conditioning without bone marrow purging or cryopreservation. Blood 1991; 77:1589-1593.
54. Sanders J, Buckner CD, Leonard JM, et al.: Late affects on gonadal function of cyclophosphamide, total-body irradiation, and marrow transplantation. Transplantation 1983; 36:252-255.
55. Keilholtz U, Korbling M, Fehrente D, et al.: Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders. Cancer 1989; 64:641-645.
56. Hinterberger-Fischer M, Kier P, Kalhs P, et al.: Fertility, pregnancies and offspring complications after bone marrow transplantation. Bone Marrow Transplant 1991; 7:5-9.
57. Linde R, Doelle GC, Alexander N, Kirchner F, Vale W, Rivier J, Ribin D: Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropinreleasing hormone agonist in normal men. N Engl J Med 1981; 305:663-668.
58. Langevitz P, Klein L, Pras M, Many A: The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol 1992; 28:157-158.